Clinical trials: Osteoarthritis (Knee / Hip)
- Condition Osteoarthritis (Knee / Hip)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Chronic Low Back Pain, Osteoarthritis
Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the efficacy of fasinumab in relieving Chronic low back pain (CLBP) as compared to placebo in participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and…
- Trial name
- FACT CLBP 1 (NCT03285646)
- Testing
- Fasinumab
- Where
- 56 sites in United States
- Volunteers
- 63 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis, Knee, Osteoarthritis, Hip
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.
- Trial name
- NCT00139776
- Testing
- Celecoxib
- Where
- 124 sites in United States, Belgium and 6 more
- Volunteers
- 875 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.
- Trial name
- FACT OA2 (NCT03304379)
- Testing
- Fasinumab, Diclofenac, Celecoxib
- Where
- 71 sites in United States
- Volunteers
- 1,650 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
The objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with Osteoarthritis (OA) who have been treated with fasinumab, compared with those treated with placebo…
- Trial name
- NCT03949673
- Testing
- Fasinumab, Naproxen, Diclofenac
- Where
- 15 sites in United States, Poland and 1 more
- Volunteers
- 23 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis, Knee, Osteoarthritis, Hip
A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform
Post-market prospective, multi-center longitudinal study to determine if mobile application-guided education and exercise paired with accurate and sensitive activity monitoring, captured from consumer wearables, can provide a…
- Trial name
- NCT03737149
- Testing
- mymobility with Apple Watch
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 6,559 people
- Sponsor
- Zimmer Biomet
Osteoarthritis
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe…
- Trial name
- NCT00313846
- Testing
- Buprenorphine transdermal patch
- Where
- 44 sites in United States
- Volunteers
- 529 people
- Sponsor
- Purdue Pharma LP
Osteoarthritis
Study of Diclofenac Capsules to Treat Osteoarthritis Pain
The purpose of this study is to determine whether Diclofenac [Test] Capsules are safe and effective for the treatment of osteoarthritis pain of the hip or knee.
- Trial name
- NCT01461369
- Testing
- Diclofenac
- Where
- 40 sites in United States
- Volunteers
- 305 people
- Sponsor
- Iroko Pharmaceuticals, LLC
Osteoarthritis, Hip, Osteoarthritis, Knee
Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
Tanezumab is a monoclonal antibody that binds to and inhibits the actions of nerve growth factor (NGF). The Nerve Growth Factor Inhibitor (NGFI) class may offer an important breakthrough in the treatment of chronic pain and is…
- Trial name
- NCT02709486
- Testing
- Tanezumab
- Where
- 148 sites in Austria, Bulgaria and 13 more
- Volunteers
- 849 people
- Sponsor
- Pfizer
Osteoarthritis, Chronic Pain
A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee
The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period.
- Trial name
- NCT00420992
- Testing
- ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)
- Where
- 81 sites in United States
- Volunteers
- 547 people
- Sponsor
- Pfizer
Osteoarthritis
Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
- Trial name
- NCT01141283
- Testing
- Buprenorphine transdermal patch
- Where
- 42 sites in United States
- Volunteers
- 290 people
- Sponsor
- Purdue Pharma LP
Osteoarthritis, Knee, Osteoarthritis, Hip
A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
The primary objective of the study is to evaluate the efficacy of fasinumab compared with placebo, when administered for up to 16 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.
- Trial name
- FACT OA1 (NCT03161093)
- Testing
- Fasinumab, Naproxen
- Where
- 139 sites in United States, Denmark and 10 more
- Volunteers
- 3,307 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis
Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly
The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).
- Trial name
- NCT00324038
- Testing
- Buprenorphine, Codeine paracetamol
- Where
- United Kingdom
- Volunteers
- 219 people
- Sponsor
- Napp Pharmaceuticals Limited
Arthritis, Osteoarthritis, Knee
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in…
- Conditions
- Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
- Trial name
- NCT01094886
- Testing
- Rivaroxaban
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Osteoarthritis
Extension Study Of Tanezumab In Osteoarthritis
Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
- Trial name
- NCT00809783
- Testing
- tanezumab
- Where
- 226 sites in United States
- Volunteers
- 2,147 people
- Sponsor
- Pfizer
Osteoarthritis
Tanezumab In Osteoarthritis Of The Hip Or Knee
The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis
- Trial name
- NCT00985621
- Testing
- tanezumab 10 mg, tanezumab 5 mg, oxycodone
- Where
- 112 sites in United States, Austria and 5 more
- Volunteers
- 614 people
- Sponsor
- Pfizer
Pain, Osteoarthritis, Hip
Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee
This clinical trial tests the pain relieving effectiveness of OROS hydromorphone, a once-daily formulation of a strong opioid against placebo in patients, who are suffering from pain due to osteoarthritis of the hip or the knee…
- Conditions
- Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
- Trial name
- NCT00980798
- Testing
- OROS hydromorphone HCl
- Where
- 12 sites in Czechia, Romania and 2 more
- Volunteers
- 288 people
- Sponsor
- Janssen-Cilag International NV
Osteoarthritis
Study of Meloxicam Capsules to Treat Osteoarthritis Pain
The purpose of this study is to determine whether Meloxicam [Test] Capsules are safe and effective for the treatment of osteoarthritis pain of the knee or hip.
- Trial name
- NCT01787188
- Testing
- Meloxicam Test Capsules
- Where
- 40 sites in United States
- Volunteers
- 403 people
- Sponsor
- Iroko Pharmaceuticals, LLC
Osteoarthritis
Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip
The purpose of this study is to investigate the analgesic efficacy and safety of tanezumab added on to diclofenac SR in patients with osteoarthritis of the knee or hip currently experiencing partial benefit from, and are…
- Trial name
- NCT00864097
- Testing
- tanezumab, diclofenac
- Where
- 77 sites in Austria, France and 8 more
- Volunteers
- 607 people
- Sponsor
- Pfizer
Osteoarthritis
Tanezumab in Osteoarthritis of the Hip or Knee (2)
Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis
- Trial name
- NCT00863304
- Testing
- tanezumab 10 mg, tanezumab 5 mg, naproxen
- Where
- 95 sites in United States
- Volunteers
- 849 people
- Sponsor
- Pfizer
Localized Primary Osteoarthritis of Hip, Localized Primary Osteoarthritis of Knee
Phase III Study of CG100649 in Osteoarthritis Patients
6-week Efficacy Study The objective of this study is to prove the safety and non-inferiority of analgesic efficacy of CG100649 2 mg vs. celecoxib 200 mg, and analgesic superiority of CG100649 2 mg vs.
- Trial name
- NCT01765296
- Testing
- CG100649, Celecoxib
- Where
- 14 sites in South Korea
- Volunteers
- 362 people
- Sponsor
- CrystalGenomics, Inc.